Medical device with a surface adapted for exposure to a blood st

Details Medical device with a surface adapted for exposure to a blood st Medical device with a surface adapted for exposure to a blood st

1996-08-27

1998-08-25

Bockelman, Mark

Surgery

Means for introducing or removing material from body for...

Treating material introduced into or removed from body...

604266, 424425, 623 2, A61M 532, A61M 2500

Patent

active

057978875

ABSTRACT:
A surface of a foreign body exposed to the flowing blood of a living being which normally would promote the aggregation of platelets in that blood to form a layer affixed to that surface and thus restrict the flow of blood past that surface or to form a blood clot detachable from that surface which when detached could trigger a stroke, heart attack or partial loss of organ function, such as plastic tubing, a balloon or the end of a catheter surgically inserted in a blood vessel or a stent implanted therein, e.g., in conjunction with percutaneous transluminal coronary angioplasty or the interior wall of a length of plastic tubing used to transport the blood of a patient, undergoing hypothermic surgery or dialysis, inhibits such aggregation when that surface is coated with a physiologically acceptable polymer, such as polyvinyl alcohol or polyvinyl chloride, containing dissolved or dispersed therein a nitrosyl-containing organometallic compound, whether ionic salt or chelate, which slowly decomposes at the body temperature and in so doing releases a platelet aggregation-inhibiting amount of nitric oxide during either the post-surgical period when the individual is a high risk candidate for post-surgical foreign body-mediated platelet aggregation on or at the situs of the foreign body or during dialysis of the blood to remove waste in those individuals with dysfunctional kidneys.

REFERENCES:
patent: 5278192 (1994-01-01), Fung et al.
patent: 5366997 (1994-11-01), Keefer et al.
patent: 5370614 (1994-12-01), Amundson et al.
patent: 5380758 (1995-01-01), Stamler et al.
patent: 5405919 (1995-04-01), Keefer et al.
patent: 5428070 (1995-06-01), Cooke et al.
patent: 5441947 (1995-08-01), Dodge et al.
patent: 5457113 (1995-10-01), Cullinan et al.
patent: 5462937 (1995-10-01), Cullinan et al.
patent: 5470307 (1995-11-01), Lindall
patent: 5482925 (1996-01-01), Hutsell
patent: 5492926 (1996-02-01), Cullinan et al.
patent: 5523092 (1996-06-01), Hanson et al.
patent: 5525357 (1996-06-01), Keefer et al.
patent: 5536241 (1996-07-01), Zapol
patent: 5591227 (1997-01-01), Dinh et al.
patent: 5599352 (1997-02-01), Dinh et al.
patent: 5605696 (1997-02-01), Eury et al.
Hobel, et al, Summary: Sodium Nitroprusside: its toxicity, metabolism, and organic distribution, Herz1 (1976), 130-136(Nr.2).
Furchgott, et al., The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine, Nature vol. 288, 27 Nov. 1980.
Palmer et al., Medical Intelligence-Drug Therapy--Sodium Nitroprusside, The New England Journal of Medicine, Feb. 6, 1975.
Palmer et al., Nitric oxide release accounts for the bilogical activity of endothelium-derived relaxing factor, Nature vol. 327, Jun. 11, 1987.
Snyder et al., Biological Roles of Nitric Oxide, Scientific American, May 1992.
Moncada et al., The L-Arginine--Nitric Oxide Pathway, The New England Journal of Medicine, Dec. 30, 1993.
Noack et al., Molecular Aspect Underlying the Vasodilator Action of Molsidomine, Journal of Cardiovascular Pharmacology, vol. 14 (Suppl. 11) 1989.
Ignarro et al., Mechanism of Vascular Smooth Muscle Relaxation by Organic Nitrates, Nitrites, Nitroprusside and Nitric Oxide: Evidence for the Involvement of S-Nitrosothiols as Active Intermediates, The Journal of Pharmacology and Experimental Therapeutics, vol. 218, No. 3, 1981.
Kowaluk et al, Spontaneous Liberation of Nitric Oxide Cannot Account for in Vitro Vascular Relaxation by S-Nitrosothiols, The Journal of Pharmacology and Experimental Therapeutics, vol. 255, Nov. 1, 1990.
Maragos et al., Complexes of 'NO with Nucleophiles as Agents for the Controlled Biological Release of Nitric Oxide. Vasorelaxant Effects. J. Med. Chem. 1991, 34-3242.
Bates et al., Nitric Oxide Generation From Nitroprusside By Vascular Tissue, Evidence That Reduction Of The Nitroprusside Anion And Cyanide Loss Are Required, Biological Pharmacology, vol. 42, Suppl. pp. S157-S1G5, 1991.
Makings et al., Caged Nitric Oxide, Stable Organic Molecules From Which Nitric Oxide Can Be Photoreleased, The Journal of Biological Chemistry, vol. 269, No. 9, Issue of Mar. 4, pp. 6282-6285, 1994.
Packer, et al, Rebound Hemodynamic Events After The Abrupt Withdrawal of Nitroprusside In Patients With Severe Chronic Heart Failure, The New England Journal of Medicine, vol. 301, No. 22, Nov. 29, 1979.
Ivankovich et al., Nitroprusside and Other Short-Acting Hypotensive Agents--Sodium Nitroprusside: Metabolism And General Considerations, International Anesthesiology Clinics, vol. 16 No. 2, Summer 1978.
Sessa et al., The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: L-Glutamine inhibits the generation of L-arginine by cultured endothelial cells, Proc. Natl. Acad. Sci. USA vol. 87, pp. 8607-8611, Nov. 1990.
Kreye et al., Possible Site of the in vivo Disposition of Sodium Nitroprusside in the Rat, Naunyn-Schmiedeberg's Arch Pharmacol (1982) 320: 260-265.
Munson et al., Principles of Pharmacology Basic Concepts & Clinical Applications, Chapman & Hall, pp. 482-483, 556.
Bogdansky, Natural Polymers as Drug Delivery Systems, Biodegradable Polymers as Drug Delivery Systems, Editors Chasin et al., Marcel Dekker, Inc., New York. Fluids, Analytical Blochemistry 126, 131-138 (1982).
Bailey, Coating of Endovascular Stents Chap 44., Textbook of Interventional Cardiology, vol. 2 Editor Topol, W.B. Saunders Company 1984.
Byron et al., Effects of Heat Treatment on the Permeability of Polyvinyl Alcohol Films to a Hydrophilic Solute, Journal of Pharmaceutical Sciences, vol. 76, No. 1 Jan. 1987.
Lewis, Controlled Release of Bioactive Agents from Lactide/Glycolide Polymers, Biodegradable Polymers as Drug Delivery Systems, Editors Chasin et al., Marcel Dekker, Inc., New York.
Hobel, et al., Summary: Studies on the Metabolism and Distribution of 14 C-Sodium Nitro-prusside in Rats.

Affiliated with

Also associated with

Rating

Medical device with a surface adapted for exposure to a blood st does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Medical device with a surface adapted for exposure to a blood st, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medical device with a surface adapted for exposure to a blood st will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-33045